Skip to main content

Month: August 2024

StoneCo Reports Second Quarter 2024 Results

GEORGE TOWN, Grand Cayman, Aug. 14, 2024 (GLOBE NEWSWIRE) — StoneCo Ltd. (Nasdaq: STNE, B3: STOC31) (“Stone” or the “Company”) today reports its financial results for its second quarter ended June 30, 2024.Adjusted EBT MSMB CTPV (Card TPV)R$652 million R$97.8 billion+45.9% year over year +17.4% year over year   Adjusted Net income Adjusted Basic EPSR$497 million R$1.61+54.4% year over year +57.2% year over year   Business Overview Stone has made significant progress in the second quarter across our strategic priorities, advancing in critical areas as we work towards our 2024 and long-term targets. Highlighting our strong growth within Financial Services, MSMB Card TPV increased by 17.4% year-over-year, representing continued market share gains within the segment. This growth was achieved with continued...

Continue reading

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2024. Second Quarter 2024 Financial and Operating SummaryRevenue was $4.1 million for the second...

Continue reading

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024. This includes the reporting of encouraging initial...

Continue reading

Nokia Corporation: Repurchase of own shares on 14.08.2024

Nokia CorporationStock Exchange Release14 August 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 14.08.2024 Espoo, Finland – On 14 August 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 953,131 3.58CEUX 568,711 3.57BATE – –AQEU – –TQEX – –Total 1,521,842 3.58* Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program started on 20 March 2024. On 19 July 2024, Nokia decided to accelerate the share buybacks by increasing...

Continue reading

NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024. Third Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights:Product revenue of $826,000 in Q3 2024, compared to $630,000 in Q3 2023 Reduced operating expenses from $3.8 million in Q3 2023 to $3.1 million in Q3 2024 Raised an additional $1.6 million using the ATM Program in Q3 2024 Completed $2.65 million private placement and entered into $3.0 million secured credit facility agreement in August 2024Evo® sEEG:Completed manufacturing...

Continue reading

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 ’23 and 43% vs. Q1 ’24 Continued gross-to-net (GTN) improvement with blended GTN across products now in the high 50 percent range, improving from the low 60 percent range last quarter Sustained growth in prescriptions for both cream and foam, with total U.S. franchise unit demand increase of 42% quarter over quarter Entered into ZORYVE co-promotion agreement with Kowa Pharmaceuticals America, Inc., expanding promotional efforts to primary care and pediatric offices in the United States Submitted Supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) foam to the Food & Drug Administration (FDA) for the treatment...

Continue reading

Forian Inc. Announces Second Quarter 2024 Financial Results

NEWTOWN, PA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended June 30, 2024. “We continued to invest in our information assets in the second quarter to further differentiate our offerings and the insights they power for our customers. We remain confident that our combination of thoughtful productization, diversification of data sources and prudent cost containment put us in solid position to manage through recent industry challenges and to continue our contribution to our customers’ success,” stated Max Wygod, Chairman and Chief Executive Officer of Forian. Second Quarter 2024 Financial ResultsForian delivered the following results for the second quarter...

Continue reading

Bright Mountain Media, Inc Announces Second Quarter 2024 Financial Results

Second quarter revenue increased to $13.0 million compared to $12.6 million for the second quarter of 2023. Half year revenue increased by $11.3 million to $25.5 million compared to $14.1 million for the same period of 2023.Boca Raton, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a global marketing service platform with capabilities in digital publishing, advertising technology, consumer insights, creative and media services, today announced its financial results for the second quarter and six months ended June 30, 2024. Matt Drinkwater, CEO of Bright Mountain, expressed enthusiasm about the company’s recent credit amendment. “We’re pleased with a key amendment we entered into in the second quarter that enhances our financial flexibility by deferring...

Continue reading

Burgundy concludes reclamation surety bonds agreement

CALGARY, Alberta, Aug. 14, 2024 (GLOBE NEWSWIRE) — Burgundy Diamond Mines Limited (ASX:BDM) (Burgundy or the Company) is pleased to confirm that the agreement with the surety providers in relation to the reclamation bonds has been formally concluded and signed by all parties, in line with previously agreed principles (see ASX announcement dated March 13th, 2024). Burgundy is required to post security with key government agencies to ensure reclamation is completed across its mining properties, as required by relevant legislation in Canada and the Northwest Territories. The security is provided in the form of either cash, letters of credit or surety bonds, or a combination of these. Significantly, Burgundy can confirm it has successfully concluded the renegotiated cash collateralisation payment schedule to extend over four years,...

Continue reading

Toll Brothers City Living and Sculptor Real Estate Announce Construction is Complete at 151 Bay Street in Jersey City as First Residents Take Occupancy

Luxury condominiums in the Powerhouse Arts District boast exceptional amenities near Grove Street PATH Station NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE: TOL), the nation’s leading builder of luxury homes, through its Toll Brothers City Living division, and Sculptor Real Estate, the real estate business of Sculptor Capital Management Inc. (“Sculptor”), are pleased to announce construction is complete and closings have commenced at 151 Bay Street in downtown Jersey City. Located in the Powerhouse Arts District, 151 Bay Street rises 34 stories and offers 259 luxury condominiums with a full complement of exceptional amenities.“We are excited to welcome our first homeowners to their new residences and thrilled with the positive response we have received from the community,” said David Von Spreckelsen, President...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.